Loading
A phase 3 trial of FOLFOXIRI and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Yanhong Deng, not yet recruiting.
Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) is a phase 3, randomised interventional study registered as NCT05427669 by Yanhong Deng, with a registry enrolment figure of 340 participants, started 2022-10-09 and due to reach its primary completion in 2025-07-01. Interventions recorded: mFOLFOXIRI; mFOLFOX6. Conditions listed: Colorectal Cancer. Primary outcome: 3-year Disease-free Survival (DFS). Colorectal eligibility wording from the registry: "Histological or cytological documentation of adenocarcinoma of the colon or rectum". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/